Proactive Investors - Run By Investors For Investors

Lots of potential for Synairgen in fibrosis, suggests broker finncap

A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor
picture of doctor
IPF causes scar tissue to build on lungs

Synairgen (LON:SNG) can build on encouraging pre-clinical results for its fibrosis treatment PXS-5382A says Finncap.

The group has confirmed a Phase I clinical trial is to start later this year for the LOXL-2 inhibitor, which is being developed in partnership with Australian firm Pharmaxis (ASX:PXS).

Management also disclosed significant interest already from numerous potential partners active and involved in R&D within this space and the potential within the NASH (liver) and IPF (lung) orphan drug space is huge

The broker added that it will update its numbers once Synairgen's management has completed its analysis of the trial data for interferon beta inhaler INEXAS (or AZD9412), a drug that was being developed with AstraZeneca until last year.

Lung fibrosis a killer

IPF (idiopathic pulmonary fibrosis) causes a build-up of scar tissue, which damages the structure of the lung and affects normal uptake of oxygen into the blood. 

The resultant stiffening of the lungs makes it increasingly difficult to breathe. 

Lab work involving lysyl oxidase-like 2 enzyme inhibitors (LOXL2) has already indicated lower tissue stiffness of around 50%.

This latest research also suggests that that oral administration of one of these compounds significantly inhibited cross-link formation, reduced fibrosis score and improved lung function.

Richard Marsden, Synairgen's cheif executive, said: “The effect of these inhibitors across different model types is very exciting, suggesting that inhibition of LOXL2 has the potential to improve lung function in severely ill patients with lung fibrosis by reducing tissue stiffness.”

IPF kills within 2-3 years and affects 132,000 people in the US, with currently available treatments generating revenues of around US$1bn, though the whole are of fibrosis market if liver disease included might eventually be worth over US$30bn according to some analysts.

Timetable points to mid-2018 as key point

Results from PXS-5382A's Phase I trial are scheduled for the middle of 2018, after which the aim is to find a partner to license the drug due to size of the potential market and number of indications it could address.

WATCH: Synairgen's chief hails exciting IPF data from LOXL2 inhibitor programme

“PXS-5382A is a very valuable candidate with potential applications in a number of fibrotic conditions with very substantial market opportunities,” said Marsden.

"The effect of this novel inhibitor across different model types is very exciting, with the latest supporting data suggesting that PXS-5382A can significantly reduce lung fibrosis and therefore has the potential to improve lung function in severely ill patients.”

Data from AstraZeneca trial expected

The final assessment of the Phase II trial of interferon beta should also be released at some point this year.

Last October, FTSE 100-listed AstraZeneca halted work on the phase IIa clinical trial after it struggled to find enough hard-to-treat cases among asthma sufferers.

At the time, Synairgen said that based on the biomarker, lung function and safety data, it may be developed to treat lung diseases where viral infections are a real problem, such as chronic obstructive pulmonary disease (COPD) though first management wanted to see the data from the AZ study of asthma patients.

"We remain positive about the potential of inhaled interferon beta, particularly for patients with COPD who suffer due to respiratory viruses,” said Marsden.

“Once we have completed the data analysis, we will provide an update on the programme and our plans for future development."

Shares rose 10% to 7.7p.


View full SNG profile View Profile

Synairgen plc Timeline

Related Articles

Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use